based on 3 analysts
66.67%
Buy
33.33%
Hold
0.00%
Sell
Based on 3 analysts offering long term price targets for Emcure Pharmaceuticals Ltd. An average target of ₹1640
Source: S&P Global Market Intelligence
Emcure Pharmaceuticals Ltd price forecast by 3 analysts
Upside of27.75%
High
₹1680
Target
₹1640.00
Low
₹1580
Emcure Pharmaceuticals Ltd target price ₹1640, a slight upside of 27.75% compared to current price of ₹1314.15. According to 3 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Emcure Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:0
Forecast
Actual
Including amortisation and stock based compensations
Emcure Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:0
Forecast
Actual
Source: S&P Global Market Intelligence
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | -7.95 % |
3 Month Return | -5.56 % |
1 Year Return | -5.54 % |
Market Stats | |
Previous Close | ₹1,283.80 |
Open | ₹1,295.00 |
Volume | 1.73L |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹24,276.45Cr |
P/E Ratio | 41.68 |
PEG Ratio | 2.62 |
Market Cap | ₹24,276.45 Cr |
P/B Ratio | 0 |
EPS | 0 |
Dividend Yield | 0 |
Sector | Pharmaceuticals |
ROE | 9.01 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
BUY | ₹24,276.45 Cr | -1.11% | 0.00 | ₹527 Cr | ₹6,658 Cr | |
BUY | ₹14,767.55 Cr | 100.04% | 0.50 | ₹461 Cr | ₹1,694 Cr | |
NA | ₹315.78 Cr | 42.44% | 0.74 | NA | NA | |
NA | ₹152.88 Cr | 5.23% | 0.60 | NA | NA | |
BUY | ₹13,205.46 Cr | 63.28% | 0.63 | ₹405 Cr | ₹4,506 Cr |
Organisation | Emcure Pharmaceuticals Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals reported robust Q2FY25 results, with a 38.2% increase in net profit to ₹201.5 crore and a 20.4% rise in revenue to ₹2,002 crore. The strong performance was driven by growth in both domestic and international markets, particularly in Canada. Despite a slight contraction in EBITDA margins, the overall financial results reflect solid operational performance and investor confidence.
Emcure Pharmaceuticals Reports Strong Q2FY25 Results - 07 Nov, 2024
Emcure Pharmaceuticals announced strong Q2FY25 results, with a 38.2% increase in PAT and 20.4% revenue growth, driven by robust international and domestic sales.
Emcure Launches Subsidiary for Dermatology Expansion - 28 Oct, 2024
Emcure Pharmaceuticals has launched Emcutix Biopharmaceuticals, a wholly-owned subsidiary aimed at enhancing its dermatology portfolio. Spearheaded by G. Sathya Narayanan, the initiative targets unmet needs in the growing Indian dermatology market, valued at $1.84 billion.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
MF Holding Up
Mutual Funds have increased holdings from 1.77% to 3.30% in Sep 2024 quarter
FII Holding Up
Foreign Institutions have increased holdings from 1.76% to 2.91% in Sep 2024 quarter
Promoter Holding Unchanged
Promoters holdings remained unchanged at 78.08% of holdings in Sep 2024 quarter
Price Dip
In the last 1 month, EMCURE stock has moved down by -8.0%
Retail Holding Down
Retail Investor have decreased holdings from 16.82% to 15.05% in Sep 2024 quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 78.08% | 0.00 | |
Foreign Institutions | 2.91% | 65.58 | |
Mutual Funds | 3.3% | 86.84 | |
Retail Investors | 15.05% | ||
Others | 0.66% |
Emcure Pharmaceuticals Ltd in the last 5 years
Lowest (41.68x)
November 21, 2024
Today (41.68x)
November 21, 2024
Industry (54.82x)
November 21, 2024
Highest (54.00x)
September 18, 2024
Emcure Pharmaceuticals Ltd’s net profit jumped 39.83% since last year same period to ₹194.57Cr in the Q2 2024-2025. On a quarterly growth basis, Emcure Pharmaceuticals Ltd has generated 35.04% jump in its net profits since last 3-months.
Read More about Earnings ResultsBearish
Neutral
Bullish
Emcure Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
Emcure Pharmaceuticals Ltd (EMCURE) share price today is ₹1314.15
Emcure Pharmaceuticals Ltd is listed on NSE
Emcure Pharmaceuticals Ltd is listed on BSE
PE Ratio of Emcure Pharmaceuticals Ltd is 41.68
PE ratio = Emcure Pharmaceuticals Ltd Market price per share / Emcure Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Emcure Pharmaceuticals Ltd(EMCURE) is 1.73L.
Today’s market capitalisation of Emcure Pharmaceuticals Ltd(EMCURE) is ₹24276.45Cr.
Emcure Pharmaceuticals Ltd(EMCURE | Price |
---|---|
52 Week High | ₹1580 |
52 Week Low | ₹1225 |
Emcure Pharmaceuticals Ltd(EMCURE) share price is ₹1314.15. It is down -16.83% from its 52 Week High price of ₹1580
Emcure Pharmaceuticals Ltd(EMCURE) share price is ₹1314.15. It is up 7.28% from its 52 Week Low price of ₹1225
Emcure Pharmaceuticals Ltd(EMCURE | Returns |
---|---|
1 Day Returns | 30.35% |
1 Month Returns | -7.95% |
3 Month Returns | -5.56% |
1 Year Returns | -5.54% |